Rosilio M, Carel J C, Blazy D, Chaussain J L
Laboratoires Lilly France, Saint Cloud, France.
Horm Res. 1997;48 Suppl 4:23-8. doi: 10.1159/000191308.
Growth hormone (GH) treatment has been proposed to improve final height in patients with short stature associated with intra-uterine growth retardation (IUGR). In this study, 30 prepubertal patients aged 9.5 +/- 0.9 years with IUGR and normal GH secretion on pharmacological testing were treated with GH. These patients had a mean birth length of -3.11 +/- 0.80 SDS, and mean growth retardation of -2.58 +/- 0.49 SDS for chronological age. GH, 1.4 IU/kg/week (= 0.07 mg/kg/day), was given for 2 years. Height gain (calculated as the difference of height SDS at baseline and after 2 years) was 1.3 +/- 0.4 SD and was not significantly correlated with height SDS or growth velocity at baseline. These data confirm that 2 years of recombinant human GH treatment increases height gain in patients with IUGR. Two years after treatment interruption, mean gain was maintained at +1.08 SDS and 83% of the children had normal height.
有人提出用生长激素（GH）治疗来提高与宫内生长迟缓（IUGR）相关的身材矮小患者的最终身高。在本研究中，对30名9.5±0.9岁的青春期前IUGR患者进行了药物测试，其生长激素分泌正常，给予生长激素治疗。这些患者出生时平均身长为-3.11±0.80 SDS，按实际年龄计算平均生长迟缓为-2.58±0.49 SDS。给予生长激素1.4 IU/kg/周（=0.07 mg/kg/天），持续2年。身高增长（计算为基线时和2年后身高SDS的差值）为1.3±0.4 SD，且与基线时的身高SDS或生长速度无显著相关性。这些数据证实，两年的重组人生长激素治疗可增加IUGR患者的身高增长。治疗中断两年后，平均增长维持在+1.08 SDS，83%的儿童身高正常。
